Brainomix vs Viz.ai

Viz.ai sells a care coordination platform to health systems, with mobile alerts and transfer messaging around the imaging read. A 2025 systematic review and meta-analysis of 12 studies and 15,595 patients found shorter door-to-groin and door-in-door-out times, and no significant difference in clinical outcomes. ContaCT was granted De Novo in February 2018 (DEN170073), and Viz.ai's July 2026 release says 2,000 hospitals and 13 FDA clearances. openFDA shows 10 510(k)s plus two De Novos.

A US health system whose security team asks for a SOC 2 Type II report starts with Viz.ai, whose Trust Center lists it. Brainomix states ISO 27001 certification and GDPR compliance, which makes it the weaker pick there.

Brainomix is the read-and-score product, founded in 2012 as an Oxford spinout, with 13 openFDA 510(k) records from May 2020 to June 2026. The vendor claims 35 or more clearances worldwide and cites £49 million raised. Its trust FAQ says patient data is stored inside the hospital, and its stroke product page offers deployment on a physical or virtual server or in a secure cloud environment, which suits a network that wants to keep stored data in-house.